LENSAR, Inc.
NASDAQ:LNSRMedical - Devices
-$0.51 today
- Market cap
- $59.63M
- Beta
- 0.87
- P/E (TTM)
- 2.4
- EPS (TTM)
- $2.42
Volume 0.06M
Average 0.09M
LNSR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
LENSAR, Inc.NASDAQ: LNSR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $1.39M fell 9.7% year over year, behind the +1.0% change in trailing-twelve-month research & development. Sequentially, it rose 6.9% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.
Context
- Research & development amounted to 9.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -9.7% toward the trailing-twelve-month pace of +1.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.62M USD
- Year-over-year change
- +5.5%
- 4-year CAGR
- -17.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.62M | +5.5% |
| FY2024 | 2024-12-31 | 5.33M | -13.2% |
| FY2023 | 2023-12-31 | 6.14M | -48.0% |
| FY2022 | 2022-12-31 | 11.81M | -4.4% |
| FY2021 | 2021-12-31 | 12.36M | — |
Research & Development vs competitors
How LNSR compares with its peers on the latest reported figures
- LNSR's LTM Mar 2026 research & development of $5.47M is the lowest of the 10 companies compared; the peer median is $21.15M.
- Its year-over-year change of +1.0% is the 5th highest of 10, against a peer median of -1.0%.
- Research & development amounts to 9.5% of revenue for LNSR, versus a peer median of 48.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.27M | +76.4% | +63.2% | — | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $31.62M | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $26.42M | +16.3% | +12.0% | 22.7% | |
| LTM Mar 2026 | $21.15M | -1.0% | +12.6% | 112.1% | |
| LTM Mar 2026 | $18.78M | -12.5% | +2.2% | 58.2% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $14.89M | -1.7% | -11.2% | 33.2% | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
| Peer median (excluding LNSR) | $21.15M | -1.0% | +9.2% | 48.5% | |
Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.46M | 35.36M | 42.16M | 53.49M | 58.44M |
| Cost of Revenue | 16.63M | 15.4M | 21.06M | 27.64M | 31.31M |
| Gross Profit | 17.83M | 19.96M | 21.11M | 25.85M | 27.12M |
| Gross Margin | 51.8% | 56.4% | 50.1% | 48.3% | 46.4% |
| Research & Development | 12.36M | 11.81M | 6.14M | 5.33M | 5.62M |
| Selling, General & Admin | 23.89M | 27.17M | 26.1M | 26.49M | 45.16M |
| Operating Expenses | 37.49M | 40.13M | 33.34M | 36.52M | 51.7M |
| Depreciation & Amortization | 2.76M | 3.41M | 3.52M | 3.93M | 4.5M |
| EBITDA | (16.84M) | (16.51M) | (10.87M) | (3.01M) | (29.78M) |
| EBITDA Margin | -48.9% | -46.7% | -25.8% | -5.6% | -51.0% |
| Operating Income | (19.65M) | (20.18M) | (12.23M) | (10.67M) | (24.58M) |
| Operating Margin | -57.0% | -57.1% | -29.0% | -19.9% | -42.1% |
| Interest Income | 34K | 17K | 85K | 103K | 91K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 51K | 263K | (2.15M) | (20.74M) | (9.7M) |
| Income Before Tax | (19.6M) | (19.91M) | (14.38M) | (31.4M) | (34.28M) |
| Pre-Tax Margin | -56.9% | -56.3% | -34.1% | -58.7% | -58.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.6M) | (19.91M) | (14.38M) | (31.4M) | (34.28M) |
| Net Margin | -56.9% | -56.3% | -34.1% | -58.7% | -58.7% |
| EPS (Basic) | (2.10) | (1.96) | (1.31) | (2.73) | (2.87) |
| EPS (Diluted) | (2.10) | (1.96) | (1.31) | (2.73) | (2.87) |
| Weighted Avg Shares | 9.37M | 10.16M | 10.97M | 11.52M | 11.96M |
| Weighted Avg Shares (Diluted) | 9.37M | 10.16M | 10.97M | 11.52M | 11.96M |
LENSAR, Inc.
NASDAQ:LNSR
Intrinsic Alpha fair value
Locked
Current Price
$4.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.